GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our gene-based therapeutic product candidates uses a common patent-protected technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease.
- TNFerade™ represents a novel approach to treating cancer in combination with radiation and/or chemotherapy by introducing tumor necrosis factor-alpha (TNF-alpha), a potent anti-cancer protein, directly into tumors. TNFerade has been evaluated for its potential use in indications such as pancreatic cancer, head and neck cancer, esophageal cancer, and rectal cancer.
- Hearing and Balance Atonal therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function.
We also are using GenVec's proprietary adenovector technology to develop vaccines for infectious diseases.
- Foot-and-mouth disease antiviral and vaccine program in collaboration with the United States Department of Homeland Security (DHS) and the United States Department of Agriculture/Agricultural Research Services (USDA-ARS) HIV vaccine in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID)
- Malaria vaccine in collaboration with U.S. Navy and PATH's Malaria Vaccine Initiative
- RSV vaccine under an SBIR grant from the NIH
- HSV-2 vaccine under an SBIR grant from NIAID
GenVec, Inc. is based in Gaithersburg, Maryland.
